Education
About Us
Working with TipRanks
Follow Us
Propanc Biopharma (PPCB)
NASDAQ:PPCB
PPCB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.25 - $145.46
Previous CloseN/A
Volume127.03K
Average Volume (3M)1.33M
Market Cap
$23.56M
Enterprise ValueN/A
Total Cash (Recent Filing)$50.76K
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta-1.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-659.87
Shares Outstanding12,806,747
10 Day Avg. Volume152,847
30 Day Avg. Volume1,330,006
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $1.25 and its highest was $145.46 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $23.56M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Currently, no data Available
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 12,806,747 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
Propanc Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-1163.67%
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Company Description
Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Technical Analysis
Verrica Pharmaceuticals
―
Applied Therapeutics
―
Repare Therapeutics
―
Barinthus Biotherapeutics
―
Telomir Pharmaceuticals, Inc.
―